ID   Ma-Mel-19
AC   CVCL_A156
SY   MaMel-19; MaMel19
DR   BTO; BTO_0005342
DR   cancercelllines; CVCL_A156
DR   Cosmic; 1181750
DR   Cosmic; 1467744
DR   Cosmic; 1846600
DR   Cosmic; 2163840
DR   Cosmic; 2686377
DR   ECACC; 13012460
DR   ESTDAB; ESTDAB-152
DR   GEO; GSM436995
DR   Progenetix; CVCL_A156
DR   Wikidata; Q54903767
RX   PubMed=17311103;
RX   PubMed=19340423;
RX   PubMed=20544847;
RX   PubMed=23348503;
RX   PubMed=23851445;
RX   PubMed=26909863;
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863).
CC   Sequence variation: Gene fusion; HGNC; HGNC:7413; MTAP + HGNC; HGNC:34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.His118Leu (c.353A>T); Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503).
CC   Omics: SNP array analysis.
CC   Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
CC   Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.
ST   Source(s): ECACC=13012460; ESTDAB=ESTDAB-152
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 8,12
ST   D16S539: 11,13
ST   D3S1358: 17
ST   D5S818: 9,12
ST   D7S820: 8,9
ST   FGA: 18,22
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 14,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   62Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 24
//
RX   PubMed=17311103; DOI=10.1371/journal.pone.0000236; PMCID=PMC1794595;
RA   Ugurel S., Thirumaran R.K., Bloethner S., Gast A., Sucker A.,
RA   Mueller-Berghaus J., Rittgen W., Hemminki K., Becker J.C., Kumar R.,
RA   Schadendorf D.;
RT   "B-RAF and N-RAS mutations are preserved during short time in vitro
RT   propagation and differentially impact prognosis.";
RL   PLoS ONE 2:E236-E236(2007).
//
RX   PubMed=19340423; DOI=10.1007/s00262-009-0701-z; PMCID=PMC11030131;
RA   Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T.,
RA   Ruiz-Cabello Osuna F., Garrido F., Garcia-Lora A.;
RT   "HLA and melanoma: multiple alterations in HLA class I and II
RT   expression in human melanoma cell lines from ESTDAB cell bank.";
RL   Cancer Immunol. Immunother. 58:1507-1515(2009).
//
RX   PubMed=20544847; DOI=10.1002/gcc.20785;
RA   Gast A., Scherer D., Chen B.-W., Bloethner S., Melchert S., Sucker A.,
RA   Hemminki K., Schadendorf D., Kumar R.;
RT   "Somatic alterations in the melanoma genome: a high-resolution
RT   array-based comparative genomic hybridization study.";
RL   Genes Chromosomes Cancer 49:733-745(2010).
//
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=26909863; DOI=10.18632/oncotarget.7503; PMCID=PMC4941330;
RA   Xie H.-P., Rachakonda P.S., Heidenreich B., Nagore E., Sucker A.,
RA   Hemminki K., Schadendorf D., Kumar R.;
RT   "Mapping of deletion breakpoints at the CDKN2A locus in melanoma:
RT   detection of MTAP-ANRIL fusion transcripts.";
RL   Oncotarget 7:16490-16504(2016).
//